Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
Pelican AI: +34,75% in Frankfurt! Ist das erst der Anfang einer großen Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
TE

WKN: A4230Y | ISIN: US88165K2006 | Ticker: G280
Frankfurt
13.11.26 | 15:25
4,918 Euro
-4,32 % -0,222
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVOGEN INC Chart 1 Jahr
5-Tage-Chart
TEVOGEN INC 5-Tage-Chart

Aktuelle News zur TEVOGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.11.Tevogen Inc.: Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement2
04.11.Tevogen Inc. - 8-K, Current Report2
30.09.Tevogen Inc. - 8-K, Current Report1
30.09.Tevogen Inc.: Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements166WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and...
► Artikel lesen
18.09.XFRA G280: WIEDERAUFNAHME/RESUMPTION289FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
TEVOGEN Aktie jetzt für 0€ handeln
10.09.Tevogen Inc. - 8-K, Current Report5
26.08.Tevogen Inc. - 8-K, Current Report1
24.08.Tevogen Inc. - S-8, Securities to be offered to employees in employee benefit plans1
30.07.Tevogen Bio Holdings Inc. - 8-K, Current Report1
29.07.Tevogen Bio becomes Tevogen Inc.5
29.07.Tevogen Bio Holdings Inc. Becomes Tevogen Inc.82WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval...
► Artikel lesen
14.07.Tevogen Bio Inc: Tevogen Bio Announces 2026 Annual Meeting of Stockholders1
10.07.Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans1
09.06.Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative710William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)...
► Artikel lesen
28.05.Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue781WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended...
► Artikel lesen
21.05.Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization586WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter...
► Artikel lesen
20.05.Tevogen Bio Holdings reports Q1 results; operating loss falls 48%3
18.05.Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi264WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on...
► Artikel lesen
12.05.Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close414WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private...
► Artikel lesen
26.03.Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth424Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates...
► Artikel lesen
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1